Filtered By:
Condition: Arthritis
Therapy: Statin Therapy
This page shows you your search results in order of date. This is page number 2.
Order by Relevance | Date
Total 33 results found since Jan 2013.
The effect of statin on major adverse cardiovascular events and mortality in patients with rheumatoid arthritis - a systematic review and meta-analysis
CONCLUSIONS: This systematic review and meta-analysis showed that statin was associated with reduction of MACE and mortality in patients with RA.PMID:35587067 | DOI:10.26355/eurrev_202205_28734
Source: European Review for Medical and Pharmacological Sciences - May 19, 2022 Category: Drugs & Pharmacology Authors: A R Rahmadi R Pranata W M Raffaello E Yonas M P Ramadhian M R R Natadikarta M R Akbar Source Type: research
Cardiovascular and Renal Morbidity in Takayasu Arteritis: A Population ‐Based Retrospective Cohort Study From the United Kingdom
ConclusionCardiovascular morbidity was increased among patients with TAK receiving primary care services in the UK. Treatment with statins and antiplatelet agents in these patients was suboptimal.
Source: Arthritis and Rheumatology - February 27, 2021 Category: Rheumatology Authors: Ruchika Goel,
Joht Singh Chandan,
Rasiah Thayakaran,
Nicola J. Adderley,
Krishnarajah Nirantharakumar,
Lorraine Harper Tags: Full Length Source Type: research
Cardiovascular and renal morbidity in Takayasu arteritis: a population ‐based retrospective cohort study from UK
ConclusionCardiovascular morbidity was increased in patients with TA attending primary care services in the UK. Treatment with statins and anti ‐platelets in these patients was suboptimal.
Source: Arthritis and Rheumatology - September 22, 2020 Category: Rheumatology Authors: Ruchika Goel,
Joht Singh Chandan,
Rasiah Thayakaran,
Nicola J Adderley,
Krishnarajah Nirantharakumar,
Lorraine Harper Tags: FULL LENGTH Source Type: research
A Multicenter, Randomized, Placebo ‐Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis
ConclusionAtorvastatin 40 mg daily is safe and results in a significantly greater reduction of LDL cholesterol level than placebo in patients with RA. The 34% CVE risk reduction is consistent with the Cholesterol Treatment Trialists ’ Collaboration meta‐analysis of statin effects in other populations.
Source: Arthritis and Rheumatology - July 21, 2019 Category: Rheumatology Authors: George D. Kitas,
Peter Nightingale,
Jane Armitage,
Naveed Sattar,
Jill J. F. Belch,
Deborah P. M. Symmons, on behalf of
the TRACE RA Consortium,
George Kitas,
Jill Belch,
Deborah Symmons,
Hawys Williams,
Shobna Vasishta,
Rebecca Storey,
Pete Tags: Original Article Source Type: research
Ability to Suppress TGF- β-Activated Myofibroblast Differentiation Distinguishes the Anti-pulmonary Fibrosis Efficacy of Two Danshen-Containing Chinese Herbal Medicine Prescriptions
Conclusion: This study suggests that a clinically efficacious cardiovascular Chinese herbal medicine (DLP) can be successfully repurposed to treat a lung disease in pulmonary fibrosis guided by TCM theory. Our comparative study between DLP and DHP demonstrated a critical requirement of suppressing both pro-inflammatory and pro-fibrotic pathways for the treatment of pulmonary fibrosis, supporting that a multi-component prescription capable of “removing both phlegm and blood stasis” will better achieve co-protection of heart and lung in PHD.
Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic ...
Source: Frontiers in Pharmacology - April 23, 2019 Category: Drugs & Pharmacology Source Type: research
Pentraxin 3 in Cardiovascular Disease
Giuseppe Ristagno1*, Francesca Fumagalli1, Barbara Bottazzi2, Alberto Mantovani2,3,4, Davide Olivari1, Deborah Novelli1 and Roberto Latini1
1Department of Cardiovascular Research, Mario Negri Institute for Pharmacological Research IRCCS, Milan, Italy
2Humanitas Clinical and Research Center-IRCCS, Milan, Italy
3Humanitas University, Milan, Italy
4The William Harvey Research Institute, Queen Mary University of London, London, United Kingdom
The long pentraxin PTX3 is a member of the pentraxin family produced locally by stromal and myeloid cells in response to proinflammatory signals and microbial moieties. The p...
Source: Frontiers in Immunology - April 16, 2019 Category: Allergy & Immunology Source Type: research
Risk Factors for Major Adverse Cardiovascular Events in Phase III and Long ‐Term Extension Studies of Tofacitinib in Patients with Rheumatoid Arthritis
ConclusionIn this post ‐hoc analysis, after 24 weeks of tofacitinib, increased HDL‐c, but not increases in LDL‐c or TC, appeared to be associated with lower future MACE risk. Further data are needed to test the cardiovascular safety of tofacitinib.This article is protected by copyright. All rights reserved.
Source: Arthritis and Rheumatology - April 16, 2019 Category: Rheumatology Authors: Christina Charles ‐Schoeman,
Ryan DeMasi,
Hernan Valdez,
Koshika Soma,
Lie‐Ju Hwang,
Mary G. Boy,
Pinaki Biswas,
Iain B. McInnes Tags: Full Length Source Type: research
Statins safe for rheumatoid arthritis patients
Patients with rheumatoid arthritis are likely to experience the same level of cardiovascular benefits as other individuals Related items fromOnMedica Lifestyle intervention in type 2 diabetes can have long-term effect Heart disease and stroke deaths plummet in Scotland Brexit could result in thousands of extra CVD deaths CHD and stroke risk seriously elevated with just one daily cigarette Obesity associated with worse mortality and higher CVD risk
Source: OnMedica Latest News - April 15, 2019 Category: UK Health Source Type: news
New Biomarkers for Atherothrombosis in Antiphospholipid Syndrome: Genomics and Epigenetics Approaches
Conclusions
In recent years, there have been many advances in the understanding of the molecular basis for vascular involvement in APS, but many areas need to be further investigated, in particular the association between altered genetic/epigenetic profiles, autoantibodies and clinical manifestations, and the effectiveness of new therapeutic strategies.
It would be interesting to apply next generation sequencing technologies like RNA-Seq along with GWAS to screen both, the gene profile and the whole transcriptome of large cohorts of primary APS patients, in order to reveal the mutations/polymorphisms, post-transcriptiona...
Source: Frontiers in Immunology - April 15, 2019 Category: Allergy & Immunology Source Type: research
Trial of atorvastatin for the primary prevention of cardiovascular events in patients with rheumatoid arthritis (TRACE RA): A multicenter, randomized, placebo controlled trial
ConclusionAtorvastatin 40mg daily was safe and resulted in significantly greater reduction of LDLc than placebo in patients with RA. The 40% (adjusted) CVE risk reduction is consistent with the Cholesterol Treatment Trialists ’ Collaboration meta‐analysis of statin effects in other populations.This article is protected by copyright. All rights reserved.
Source: Arthritis and Rheumatology - April 14, 2019 Category: Rheumatology Authors: George D. Kitas,
Peter Nightingale,
Jane Armitage,
Naveed Sattar,
Jill J.F. Belch,
Deborah P.M. Symmons,
The TRACE RA consortium,
George Kitas,
Jill Belch,
Deborah Symmons,
Hawys Williams,
Shobna Vasishta,
Rebecca Storey,
Peter Nightingale,
Tags: Full Length Source Type: research
Is Rheumatoid Arthritis a Cardiovascular Risk Equivalent to Diabetes?
ConclusionFindings from the present study suggest that while CVD risk in RA is elevated, it is lower in magnitude compared to the CVD risk associated with diabetes. It therefore may not be appropriate to consider RA a diabetes risk‐equivalent with respect to hyperlipidemia management.This article is protected by copyright. All rights reserved.
Source: Arthritis Care and Research - February 6, 2018 Category: Rheumatology Authors: Jeffrey R Curtis, Shuo Yang, Jasvinder A. Singh, Fenglong Xie, Lang Chen, Huifeng Yun, Paul Muntner, Shia T Kent, Emily B. Levitan, Monika M. Safford, Kenneth G. Saag, Jie Zhang Tags: Brief Report Source Type: research
Anti-inflammatory drug may help prevent heart attacks
Conclusion
This well-conducted study shows promising signs that canakinumab may reduce the risk of future heart attacks and other cardiovascular events in people who've had them in the past.
But before any changes are made to the current licensing of this drug, further research is needed to confirm the beneficial effects and the optimal dose.
Most importantly, researchers will need to focus on the observation that the drug lowered white blood cell counts and increased the risk of fatal infection.
They estimated around 1 in every 300 people taking canakinumab would die of a fatal infection. This number, while low, is sti...
Source: NHS News Feed - August 30, 2017 Category: Consumer Health News Tags: Heart/lungs Source Type: news
Risk-benefit profile of statin therapy 'may be more positive than expected'
This study showed that providing an effective low-cost statin therapy to 10,000 patients for five years would prevent major cardiovascular events such as heart attacks, strokes and coronary artery bypasses in 1,000 people with preexisting vascular disease, as well as 500 people who are at increased risk but have not yet had a vascular event. By contrast, only 50 to 100 cases of symptomatic adverse events would be expected over the same period, as well as 50 to 100 new cases of diabetes, five cases of myopathy and between five and ten haemorrhagic strokes. Should statins be more widely used? Currently, about six million peo...
Source: Arthritis Research UK - September 8, 2016 Category: Rheumatology Source Type: news
Prevention of Stroke in Rheumatoid Arthritis
Abstract
The risk of cerebrovascular disease is increased among rheumatoid arthritis (RA) patients and remains an underserved area of medical need. Only a minor proportion of RA patients achieve suitable stroke prevention. Classical cardiovascular risk factors appear to be under-diagnosed and undertreated among patients with RA. Reducing the inflammatory burden is also necessary to lower the cardiovascular risk. An adequate control of disease activity and cerebrovascular risk assessment using national guidelines should be recommended for all patients with RA. For patients with a documented history of cerebrovascu...
Source: Current Neurology and Neuroscience Reports - October 20, 2015 Category: Neuroscience Source Type: research
